Processes and intermediates for quinine, quinidine, isomers and derivatives thereof

ABSTRACT

The preparation of quinine, quinidine, isomers and derivatives thereof from the correspondingly substituted 4-methylquinoline and 1-acyl(or 1-H)-3-vinyl(or lower alkyl)-4-piperidine acetic acid esters (or acetaldehyde) through alternative series of reaction steps which comprise, condensation, halogenation, deacylation, reduction, cyclization and hydroxylation, is described. Also described is the preparation of 1-acyl(or 1-H)-3vinyl-4-piperidineacetic acids and esters thereof and 1-acyl-3vinyl-4-piperidineacetaldehyde utilizing the corresponding 7acyldecahydro-2H-pyrido(3,4-d)azepin-2-one, prepared from 2-acyl1,3,4,7,8,8a-hexahydro-6(2H)-isoquinolone. The end products are useful as antimalarial and antiarrhythmic agents.

Gutzwiller et a].

[ 1 Dec. 30, 1975 PROCESSES AND INTERMEDIATES FOR QUININE, QUINIDINE, ISOMERS AND DERIVATIVES THEREOF Inventors: Juerg Albert Walter Gutzwiller,

Bettingen, Switzerland; Milan Radoje Uskokovie, Upper Montclair, NJ.

Assignee: Hoffman-La Roche Inc., Nutley,

Filed: Aug. 1, 1973 Appl. No.: 384,525

Related US. Application Data Division of Ser. No. 212,774, Dec. 27, 1971, Pat. No. 3,772,302, which is a continuation-in-part of Ser. No. 104,784, Jan. 7, 1971, abandoned, which is a continuation-in-part of Ser. No. 837,354, June 27, 1969, abandoned, which is a continuation-in-part of Ser. No. 741,914, July 2, 1968, abandoned.

[52] US. Cl. 260/284; 260/288 R [51] Int. Cl. C07D 453/04 [58] Field of Search 260/288 R, 284

[56] References Cited UNITED STATES PATENTS 1,997,440 4/1935 Tomerkin 260/284 l,997,719 4/1935 Cretcher et a1... 260/284 2,172,608 9/1939 Butler et a1 260/284 2,892,832 6/1959 Rudner 260/284 3,163,653 12/1964 Ochiai ..260/284 OTHER PUBLICATIONS Dictionary of Organic Compounds, 1965, by Oxford University Press pp. 266, 268, 269, 708, 760, 1636-1638, 2836-2839.

Chemical Abstracts, various Quinine derivative listed.

Primary ExaminerDonald G. Daus Assistant ExaminerDavid E. Wheeler Attorney, Agent, or FirmSamuel L. Welt; Bernard S. Leon; William G. Isgro [57] ABSTRACT The preparation of quinine, quinidine, isomers and derivatives thereof from the correspondingly substituted 4-methylquinoline and l-acyl(or l-I-I)-3-vinyl(or lower alkyl)-4-piperidine acetic acid esters (or acetaldehyde) through alternative series of reaction steps which comprise, condensation, halogenation, deacylation, reduction, cyclization and hydroxylation, is described. Also described is the preparation of 1-acyl(or l-l-l)-3-viny1-4-piperidineacetic acids and esters thereof and 1-acyl-3-vinyl-4-piperidineacetaldehyde utilizing the corresponding 7-acyldecahydro-2H- pyrido[3,4-d]azepin-2-one, prepared from 2-acyll,3,4,7,8,8a-hexahydro-6(2I-I)-isoquinolone. The end products are useful as antimalarial and antiarrhythmic agents.

20 Claims, No Drawings 1 PROCESSES AND INTERMEDIATES FOR QUININE, QUINIDINE, ISOMERS AND DERIVATIVES THEREOF CROSS-REFERENCE TO RELATED 5 APPLICATIONS This is a division, of application Ser. No. 212,774 filed December 27, 1971, now US. Pat. No. 3,772,302, issued Nov. 13, 1973 which in turn is a c.i.p. of Ser. No. 104,784, filed 1/7/71, now abanl0 doned, which is a c.i.p. of Ser. No. 837,354, filed 6/27/69, now abandoned, which is a c.i.p. of Ser. No. 741,914, filed 7/2/68, now abandoned.

BRIEF SUMMARY OF THE INVENTION The invention relates to a process for preparing quinine, quindine, isomers and derivatives thereof which comprises:

a. condensing the correspondingly substituted 4- methylquinoline with racemic or optically active cis or trans l-acyl (or l-1-I)-3-vinyl(or lower alkyl)-4- piperidineacetic acid ester to yield the corresponding racemic or optically active cis or trans 4-{3-[ l-acyl(or l -1:l)-3 -vinyl(or lower alkyl)-4-piperidyl]-2-oxopropyl}quinoline;

b. deacylating, if necessary, and reducing the product of step (a) to yield the corresponding racemic or optically active epimeric 4-{cis or trans-3-[3-vinyl(or lower alkyl)-4-piperidyl]-2-hydroxypropyl quinolines. If desired, this reaction product can be acylated to yield racemic or optically active epimeric 4-{cis or trans-3- [3-vinyl(or lower alkyl)-4-piperidyl]-2-acyloxypropyl}quinolines or dehydrated to yield racemic or optically active cis or trans 4-{cis or trans 3-[3-vinyl(or' lower alkyl)-4-piperidyl]prop-l-enyl}quinolines;

c. an alternate process comprises condensing the correspondingly substituted 4-methylquinoline with racemic or optically active cis or trans l-acyl-3-vinyl(or lower alkyl)-4-piperidineacetaldehyde to yield the corresponding racemic or optically active epimeric 4-{cis or trans-3-[l-cayl-3-vinyl(or lower alkyl)-4- -piperidyl]-2hydroxypropyl quinolines, and deacylating this reaction product to yield the corresponding racemic or optically active epimeric 4-cis or trans-3- [3-vinyl (or lower alkyl)-4piperidyl]-2-hydroxy-l propyl}quinolines;

d. cyclizing the hydroxy, acyloxy or prop-l -enyl quinoline product of step (b) or (c) to yield the corresponding racemic or optically active 4-{a-[5-vinyl(or lower alkyl)-2-quinuclidinyl]-methyl}quinoline, epimeric in positions 2 and 5;

e. hydroxylating the product of step (d) to yield the corresponding racemic or optically active a-[5-vinyl(or lower alkyl)-2-quinuclidinyl]-4-quinolinemethanol, epimeric in positions a, 2 and 5; and

f. recovering the desired reaction product.

An alternate process comprises:

g. halogenating the product of step (a) above to yield the corresponding racemic or optically active epimeric 4-{cis or trans 3[l-acyl-3-vinyl(or lower alkyl)-4-- piperidyl]- l .f-halo-Z-oxopropyl} quinolines;

h. reducing the product of step (g) with subsequent cyclization to yield a mixture of the corresponding racemic or optically active epimeric 4-{cis or trans-3- [l-acyl-3-vinyl(or lower alkyl)-4-piperidyl]-l ,2-oxa- 'propyl}quin0lines;

i. deacylating the product of step (g) to yield a mixture of the corresponding racemic or optically active epimeric 4-{cis or trans 3-[3-vinyl(or lower alkyl)-4- piperidyl]- l ,2-oxapropyl} quinolines;

j. cyclizing the product of step (h) to yield the corresponding racemic or optically active a-[5-vinyl(or lower alkyl)-2-quinuclidinyl]-4-quinolinemethanol, epimeric in positions a, 2 and 5; and

k. recovering the desired reaction product.

The end products are useful as antimalarial and antiarrhythmic agents.

In another aspect, the invention relates to a process for preparing racemic or optically active cis or trans l-acyl(or l-H)-3-vinyl-4-piperidineacetic acid and esters thereof and racemic or optically active cis or trans l-acyl-3-vinyl-4-piperidineacetaldehyde by:

a. nitrosating a racemic or optically active cis or trans 7-acyl-decahydro-2I-I-pyrido[3,4-d]azepin-2-one to yield the corresponding racemic or optically active cis or trans 7-acyl- 1 -nitroso-decahydro-2H-pyrido[3 ,4- d]azepin-2-one;

b. pyrrolyzing the reaction product of step (a) to yield the corresponding racemic or optically active cis or trans l-acyl-3-vinyl-4-piperidineacetic acid; and

c. hydrolyzing, if desired, and esterifying the reaction product of step (b) to yield the corresponding racemic or optically active cis or trans l-acyl(or l-I-I)-3-vinyl-4- piperidineacetic acid ester; and

d. reducing and acylating the reaction product of step (c) to yield racemic or optically active cis or trans l-acyl-3 -vinyl 4-piperidineacetaldehyde.

In a further aspect, the invention relates to an alternate process for preparing racemic or optically active cis and trans l-acyl(or l-H)-3-vinyl-4-piperidineacetic acid and esters thereof by:

a. alcoholizing a racemic or optically active cis or trans 7-acyl-decahydro-2I-l-pyrido[3,4-d]azepin-2-one to yield the corresponding racemic or optically active cis or trans 1-acyl-3-(2-aminoethyl)-4-piperidineacetic acid esters;

b. methylating the reaction product of step (a) to yield the corresponding racemic or optically active cis or trans l-acyl-3-( 2-dimethylaminoethyl )-4- piperidineacetic acid esters;

c. oxidizing the reaction product of step (b) to yield the corresponding racemic or optically active cis or trans l-acyl-3-(Z-dimethylaminoethyl)-4-piperidineacetic acid ester N-oxide; and

d. pyrolyzing the reaction product of step (c) to yield the desired acetic acid and esters thereof.

In still another aspect, the invention relates to a process for preparing racemic or optically active cis or trans 7-acyl-decahydro-2H-pyrido[ 3 ,4-d]azepin-2-one which comprises:

a. hydrogenating a racemic or optically active 2-acyll,3,4,7,8,8a-hexahydro-6(2H)-isoquinolone to yield the corresponding racemic or optically active cis or trans 2-acyl-octahydro-6(2I-I )-isoquinolone; and

b. converting the reaction product of step (a), through a Schmidt Rearrangement, to the corresponding racemic or optically active cis or trans 7-acyldecahydro-2H-pyrido[3 ,4-d azepin-2-one.

Alternatively, by a process which comprises:

a. converting, through a Schmidt Rearrangement, a racemic or optically active 2-acyl-l ,3,4,7,8,8a-hexahydro-6(2H)-isoquinolone to the corresponding -racemic or optically active 2-acyl-l,2,3,4,7,8,9,9a-octahydro- 6H-pyrido[3,4-d]azepin-6-one; and

b. hydrogenating the reaction product of step (a) to yield the corresponding racemic or optically active cis or trans 7-acyl-decahydro-2H-pyrido[3,4-d]azepin- 2-one.

In yet another aspect, the invention relates to novel compounds.

3 DETAILED DESCRIPTION OF THE INVENTION The term lower alkyl as used herein denotes a hydrocarbon group containing l-7 carbon atoms such as methyl, ethyl, propyl, butyl and the like; methyl and ethyl are preferred. The term lower alkoxy denotes a lower alkyl ether group in which the lower alkyl moiety is described as above, such as methoxy, ethoxy, propoxy, butoxy and the like; methoxy and ethoxy are preferred. The term halogen denotes all of the halogens, i.e., bromine, chlorine, fluorine and iodine. Preferred are chlorine and bromine. The term acyl denotes lower alkanoyl of 1-7 carbon atoms such as formyl, acetyl, propanoyl, butanoyl, heptanoyl, and the like; ar-lower alkanoyl, preferably phenyl-lower alkanoyl wherein phenyl may be substituted by one or more lower alkyl, lower alkoxy or halogen groups such as benzoyl and the like. The term aryl means phenyl which may be substituted by one or more lower alkyl, lower alkoxy or halogen groups. The term aralkyl means a hydrocarbon group of 7-12 carbon atoms such as benzyl, phenethyl, phenylpropyl and the like. The term acyloxy means an acyloxy wherein the acyl moiety is as hereinbefore described, for example, lower alkanoyloxy and ar-lower alkanoyloxy.

The process for preparing quinine, quinidine, isomers and derivatives thereof is exemplified by Reaction Scheme la, la, la", Ib, Ib' and lb".

Scheme wherein m is 0, l or 2; R is hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy, or when m is 2, R taken together with an adjacent R is also methylenedioxy; R is vinyl or lower alkyl, preferably ethyl; R is hydrogen or lower alkyl; R is hydrogen or acyl; and R is lower alkyl, aryl or ar-lower alkyl. As is evident from the above when m is 2, R or the like is individually selected from the various groupings hereinbefore described.

Compounds of the formula Ia and Ila above are useful as antimalarial and antiarrhythmic agents In Reaction Scheme Ia, 4-methyl-quinolines of formula X, which are known compounds or are analogs of known compounds readily obtained by known procedures, are condensed with l-acyl (or l-I-l)-3(R)-vinyl(or lower alkyl)-4(S)-piperidineacetic acid ester of formula IXa, antipode or its racemate which are known compounds, are analogs of known compounds readily obtained by known procedures, or are prepared as hereinafter described, in the presence of a base, for example, sodium hydride, an alkali metal alkoxide such as sodium methoxide, or lithium dialkylamide such as lithium diisopropylamide to yield 4-{3-[ l-acyl(or l-l-I 3(R)-vinyl(0r lower alkyl)-4(S)-piperidyl]-2-oxopropyl}quinoline of formula VIIIa, antipode or its racemate. The condensation is suitably carried out at room temperature; however, temperatures above or below Vlllu room temperature may be employed. Preferably, the condensation is conducted at a temperature within the range of about 70 and about 50C. Moreover, the condensation can be suitably carried out in the presence of an inert organic solvent, for example, a hydrocarbon, such as benzene, hexane and the like, or an ether such as ether, tetrahydrofuran or dioxane, or dimethylformamide or hexamethylphosphoramide.

The 4-{3-[1-acyl(or l-H )-3(R)-vinyl(or lower alkyl)-4(S)piperidyll-Z-oxopropyllquinoline of formula Villa, antipode or its racemate is converted to the mixture of epimeric 4-{3-[3(R)vinyl(or lower alkyl)- 4(S)-piperidyl]-2-hydroxypropyl]quinolines of formula Vla, their antipodes or racemates by simultaneous deacylation, if necessary, and reduction. The deacylation and reduction are conveniently effected utilizing a reducing agent, for example, diisobutylaluminum hydride, sodium aluminum hydride and the like, in an inert organic solvent, for example, a hydrocarbon such as benzene or toluene, ether, tetrahydrofuran and the like. The deacylation and reduction are suitably carried out at room temperature or below, preferably, at a temperature within the range of about -70 to about 25C. The reduction and deacylation can also be carried out stepwise, i.e., by first reducing a compound of formula VIlIa, wherein R is acyl, with sodium borohydride, followed by deacylation utilizing, for example, aqueous hydrochloric or sulfuric acid as the deacylating agent. If desired, the compound of formula Vla can be esterified to the corresponding The cyclization of epimeric 4- {3-[3(R)-vinyl(or lower alkyl)4(S)-piperidyl]-2-hydroxy(or acyloxy)- propyllquinolines of formulas Vla and Vlla, their antipodes or racemates, respectively and cis and trans 4 {3-[3(R)-vinyl(or lower alkyl)-4(R)-piperidyl]prop- 1-enyl}quinolines of formula Va, their antipodes or racemates to 4-{a-[5(R)-vinyl(or lower alkyl)-4(S)- quinuclidin2(S) and 2(R)-yl]-methyl}quinolines of formulas Illa and IVa, their antipodes or its racemate is carried out utilizing a cyclizing agent, for example, an organic acid, such as glacial acetic acid or the like. The cyclization is suitably carried out at room temperature; however, temperatures above or below room temperature may also be employed. It is preferred to employ a temperature within the range of about to about 100C. Moreover, the cyclization can be conveniently conducted in the presence of an inert organic solvent, for example, a hydrocarbon such as benzene or toluene, or an ether, such as diethyl ether or tetrahydrofuran.

The hydroxylation of the compounds of formulas lIla and lVa or their racemates to a(R)-[5(R)-vinyl(or lower alkyl)-4(S)-quinuclidin-2(S)-yl]-4-quinolinemethanol of formula la, its antipode or racemate and a(S)-[5(R)-vinyl(or lower alkyl)-4(S)-quinuclidin- 2(R)-yll-4-quinolinemethanol of formula lla, its antipode or racemate, respectively, is caarried out, for

mixture of epimeric 4-{3-[3(R)-vinyl(or lower alkyl)- 4 S )-piperidyl -2-acyloxypropyl} quinolines of formula Vlla, their antipodes or racemates utilizing known procedures, for example, reaction with the corresponding organic acid in the presence of a catalyst, such as boron trifluoride. Alternatively, if desired, the compound of formula Vla can be converted to cis and trans 4-{3-[3(R)-vinyl(or lower alkyl)-4(R)piperidyl]- prop-1 -enyl}quinolines of formula Va, their antipodes or racemates utilizing a dehydrating agent such as thionyl chloride, phosphorus oxychloride, phosphorus pentachloride and the like, in the presence of an organic base, for example, a tertiary amine such as pyridine, triethylamine and the like, at a temperature within the range of about 0 to about room temperature.

example, in the presence of molecular oxygen and a reducing agent, such as dimethylsulfoxide, pyridine, triphenylphosphine, platinum black, or a trialkylphosphite, such as triethylphosphite,or the like, in a strongly basic solution.

A suitable base for the reaction described above comprises, for example, an alkali metal alkoxide, such as potassium t-butoxide, sodium t-butoxide, sodium isoamylate, sodium methoxide or the like, or an alkali metal amide, such as lithium diisopropylamide, sodium amide or the like. Conveniently, a solvent such as di methylsulfoxide, dimethylformamide, hexamethylphosphoramide, pyridine, t-butanol, a hydrocarbon such as benzene or toluene, an ether such as tetrahydrofuran, dioxane or the like, or mixtures thereof can be utilized. A preferred reaction medium comprises a mixture of dimethylsulfoxide and t-butanol in the presence of potassium t-butoxide.

H (CH0 1;;

XXIIIEX 7 wherein R R and m are as previously described and R is acyl.

In Reaction Scheme Ia an alternative process for the preparation of compounds of formula Vla is described. 4-Methyl-quinolines of formula X are condensed with l-acyl-3(R)-vinyl-(or lower alkyl )-4( S piperidineacetaldehyde of formula XXIlla, its antipode suitably carried out at room temperature; however, temperatures above and below room temperature may be employed. Moreover, the deacylation can be suitably carried out in the presence of an inert organic solvent, for example, a lower alkanol, such as methanol or ethanol, or an ether, such as tetrahydrofuran or dioxane.

(Rrl

( lim XXIO or racemate which are new compounds and are prepared as hereinafter described, in the presence of base, for example, sodium hydride, an alkali metal alkoxide such as sodium methoxide, or lithium dialkylamide such as lithium diisopropylamide to yield the mixture of epimeric 4- 3-[l-acyl-3(R)-vinyl-(or lower alkyl)- 4(S)-piperidyl]-2-hydroxypropyl quinolines of formula XXIVa, their antipodes or racemates. The compounds of formula XXIVa are deacylated to the corresponding mixture of epimeric 4- 3(R)-vinyl(or lower alkyl)-4(S)-piperidyl]-2-hydroxypropyl quinolines of formula VIa, their antipodes or racemates, utilizing a deacylating agent, for example, alkali metal hydroxide, such as sodium hydroxide or potassium hydroxide, a reductive deacylating agent such as lithium aluminum hydride, sodium aluminum hydride, diisobutyl aluminum hydride and the like. Preferably, the deacylation is wherein R R R'., and m are as previously described and X is halogen.

In Reaction Scheme la", an alternative process for the conversion of compounds of formula VIIIa' to the compounds of formulas la and [la is described. The conversion of the 4-{3-[l-acyl-3(R)-vinyl(or lower alkyl)-4(S)-piperidy1]-2-oxopropyl}quinoline of formula VIIIa', its antipode or racemate to the corresponding mixture of epimeric 4-{3-[ l-acyl-3(R)-viny- 1(or lower alkyl)-4(S)-piperidyl]-lg-halo-2-oxopropyl} quinolines of formula XXa, their antipodes or race mates, respectively, is effected utilizing a halogenating agent such as N-bromo-succinimide, N-chloro-succinimide, N-bromoacetamide and the like. The halogenation can be conducted in an inert organic solvent, for example, a hydrocarbon such as benzene, toluene and the like, a halogenated hydrocarbon such as carbon tetrachloride; an ether such as diethylether, tetrahydrofuran, dioxane and the like. Conveniently, the reaction can be initiated by a free radical catalyst such as dibenzoylperoxide or by irradiation with infrared. The temperature is not critical, however, it is preferred to conduct the reaction at a temperature in therange of about room temperature and the reflux temperature of the reaction mixture.

The conversion of the epimeric compounds of formula XXa, their antipodes or racemates to the corresponding mixture of diastereomeric 4-{3-l-acyl-3(R)- vinyl(or lower alkyl)-4(S)-piperidyl]-lg-exapropyl} quinolines of the formula XXla, their antipodes of racemates can be effected utilizing a reducing agent, for example, alkali metal hydrides such as sodium borohydride, potassium borohydride, lithium tritertiarybutoxyaluminum hydride and the like. The reduction is conveniently effected in an inert organic solvent, for example, aliphatic alcohols such as methanol, ethanol and the like; ethers such as diethylether, tetrahydrofuran, dioxane and the like, at a temperature in the range of about -70C. and about the reflux temperature of the reaction mixture.

The conversion of the compound of formula XXla to the corresponding mixture of the diastereomeric 4-{3- propyl}quinolines of the formula XXlIa, their antipodes or racemates is effected using a deacylating agent, for example, alkali hydroxides such as sodium hydroxide, potassium hydroxide, or a reducing deacylating agent, for example, dialkylaluminum hydride such as HC-CH lllb diisobutylaluminum hydride, or an alkali metal aluminum hydride such as lithium aluminum hydride, sodium aluminum hydride and the like. The deacylation is conveniently conducted in the presence of an inert organic solvent, for example, lower alkanols such as methanol, ethanol and the like, hydrocarbons such as toluene and the like, ethers such as diethylether, tetrahydrofuran and the like. The deacylation temperature is not critical. Conveniently, it may be in the range of about 70C. to about the reflux temperature of the reaction mixture.

The conversion of the compounds of formula XXlla to the corresponding mixture comprising a(R)-[5(R)- vinyl(or lower alkyl)4(S)-quinuclidin-2(S)-yl]-4- quinolinemethanol of formula la, its antipode or racemate and a(S)-[4(R)-vinyl(or lower alkyl)-4(S)-quinuclidin-2(R)-yl]-4-quinolinemethanol of formula lIa, its antipode or racemate is effected by reaction with a weak organic or inorganic protonic acid, for example, water, ammonium chloride, lower alkanols such as methanol, ethanol and the like, Lewis acids such as aluminum oxide, aluminum chloride, boron trifluoride and the like. Conveniently, conversion is conducted in v the presence of an inert organic solvent, for example,

dichloromethane, carbontetrachloride, chloroform and H R COOH H2 I 4 3 N Continued wherein R R R R R and m are as previously described.

The hereinafter described reaction steps of Reaction Scheme lb are effected utilizing the procedures and conditions set forth in Scheme la. The 4-methyl-quiholine of formula X is condensed with l-acyl(or l-H) formulas [11b and lVb are hydroxylated to a(R)-[5(S)- vinyl(or lower alkyl)-4(S)-quinuclidin-2(S)-yl]-4- quinolinemethanol of formula lb, its antipode or racemate and a(S)-[5(S)-vinyl(or lower alkyl)-4(S)-quinuclidin-2(R)-yl]-4-quinolinemethanol of formula IIc, its antipode or racemate, respectively.

XXIIIb Vlb 3(S)-vinyl(or lower alkyl)-4(S)-piperidineacetic acid 50 wherein R R RC, and m are as previously deester of formula lXb, its antipode or racemate to yield 4- {3-[l-acyl(or l-H)-3(S)-viny1(or lower alkyl)4(S)- piperidyl]-2-oxopropyl}quinoline of formula VIllb, its antipode or racemate. The compound of formula VIIIb is deacylated, if necessary, and reduced to the mixture of epimeric 4-{3-[3(S)-vinyl(or lower alkyl)-4(S)- piperidyl]-2-hydroxypropyl quinolines of formula Vlb, their antipodes or racemates. If desired, the compounds of formula Vlb can be esterified to the mixture of epimeric 4-{3-[3(S)-vinyl(or lower alkyl)-4(S)- piperidyl]-2-acyloxypropyl}quinolines of formula VIIb, their antipodes or racemates or, alternatively, it can be converted to cis and trans 4-{3-[ 3(S)-vinyl(or lower alkyl)-4(R)-piperidyl]-prop-l -enyl}quinolines of formula Vb, their antipodes or racemates. The compounds of formula Vb, Vlb or VIIb are cyclized to 4-{a-[5(S )-vinyl(or lower alkyl)-4(S)quinuclidin-2(S) and 2(R)-yl]methyl}quinolines of formulas lllb and lVb, their antipodes or racemates. The compounds of scribed.

The hereinafter described reaction steps of Reaction Scheme lb are effected utilizing the procedures and conditions set forth in Scheme la. 4-Methyl-quinolines of formula X are condensed with l-acyl-3(S)-vinyl(or lower alkyl)-4(S)-piperidineacetaldehyde of formula XXllIb, its antipede or racemate which are new compounds and are prepared as hereinafter described, to yield the mixture of epimeric 4-{3-[l-acyl-3( S)-vinyquinolines of formula XXIVb, their antipodes or racemates. The compounds of formula XXIVb are deacylated to the corresponding mixture of opimeric 4-{ 3- [3(S)vinyl(or lower alkyl)-4(S)-piperidyl]-2-hydroxypropyl}quinolines of formula Vlb, their antipedes or racemates.

The hydroxylation of the compound of Formulas lIIa,b IVa,b to the end products of Formulas la,b-Ila,b,

R1 )m N/ IIIa., b- IVa;b 1 Ia.,b-IIa,b

can also be effected utilizing molecular oxygen and a lizing a chloroformate such as benzylchloroformate. catalyst such as platinum, tris(triphenylphosphine)r- The compounds of formula XXXI are converted to the hodium chloride or the like by oxidation utilizing a compounds of formula XXXII by tosylation with a compound such as selenium dioxide, ruthenium tetroxcompound such as p-toluenesulfonylchloride or p-tolide, palladium acetate, mercuric acetate, thallium tri- 20 uenesulfonic acid anhydride in a solvent such as pyriacetate, manganese dioxide, cerium (IV) oxide, or the dine. The conversion of the compounds of formula like. XXXII to the corresponding compound of formula Alternate procedures for the conversion of the com- XXXIII is effected by the removal of the N-carbobenpounds of Formula Vla,b to the corresponding comzoxy group utilizing, for example, acetic acid/hydrogen pound of Formula lIla,b-IVa,b are exemplified in Reac- 25 bromide mixture. The cyclization of the compounds of tion Scheme V. formula XXXIlI to the corresponding compound of H R 2 c H 5 l m i R 1 Vlu,b

S02--OH3 xxxu XXXI u lo-blVu,b

The conversion of compounds Vlab to the corre formula IlIa,b-IVa,b is effected by heating in an orv spending compounds of formula XXXI is effected ganic solvent such as methanol, ethanol, dimethylformamide, dimethylsulfoxide and the like.

(Rum

(or lower alkyl)-4(S)piperidyl]- l g-halo-2-oxopropyl} quinolines of formula XXb, their antipodes or racemates, respectively, is effected utilizing a halogenating agent such as N-bromo-succinimide, N-chloro-succinimide, N-bromoacetamide and the like. The halogenation can be conducted in an inert organic solvent, for example, a hydrocarbon such as benzene, toluene and the like. a halogenated hydrocarbon such as carbon tetrachloride; an ether such as diethylether, tetrahydrofuran, dioxane and the like. Conveniently, the reaction can be initiated by a free radical catalyst such as dibenzoylperoxide or by irradiation with infrared. The temperature is not critical, however, it is preferred to conduct the reaction at a temperature in the range of about room temperature and the reflux temperature of the reaction mixture.

The conversion of the epimeric compounds of formula XXb, their antipodes or racemates to the corresponding mixture of diastereomeric 4-{3-[ l-acyl-3(S)- vinyl(or lower alkyl)-4(S)-piperidyl]-l,2-oxapropyl}quinolines of the formula XXIb, their antipodes or racemates can be effected utilizing a reducing agent, for example, alkali metal hydrides such as sodium borohydride, potassium borohydride, lithium tritertiarybutoxyaluminum hydride and the like. The reduction is conveniently effected in an inert organic solvent, for example, aliphatic alcohols such as methanol, ethanol and the like; ethers such as diethylether, tetrahydrofuran, dioxane and the like, at a temperature in the range of about 70C. and about the reflux temperature of the reaction mixture.

The conversion of the compound of formula XXIb to the corresponding mixture of the diastereomeric 4-{3- [3(S)-vinyl(or lower alkyl)-4(S)-piperidyl]-l,2-oxapropyllquinolines of the formula XXlIb, their antipodes or racemates is effected using a deacylating agent, for example alkali hydroxides such as sodium hydroxide, potassium hydroxide, or a reducing deacylating agent, for example, dialkylaluminum hydride such as diisobutylaluminum hydride, or an alkali metal aluminum hydride such as lithium aluminum hydride, sodium aluminum hydride and the like. The deacylation is conveniently conducted in the presence of an inert organic solvent, for example, lower alkanols such as methanol, ethanol and the like, hydrocarbons such as toluene and the like, ethers such as diethylether, tetrahydrofuran and the like. The deacylation temperature is not critical. Conveniently, it may be in the range of about -70C. to about the reflux temperature of the reaction mixture.

The conversion of the compounds of formula XXIIb to the corresponding mixture comprising a(R)-[5(S)- vinyl(or lower alkyl)-4(S)-quinuclidin-2(S)-yl]-4- quinolinemethanol of formula lb, its antipode or racemate and a(S)-[5(S)-vinyl(or lower alkyl)-4(S)-quinu clidin-2(R)-yl]-4-quinolinemethanol of formula IIb, its antipode or racemate is effected by reaction with a weak organic or inorganic protonic acid, for example, water, ammonium chloride, lower alkanols such as methanol, ethanol and the like, Lewis acids such as aluminum oxide, aluminum chloride, boron trifluoride and the like. Conveniently, conversion is conducted in the presence of an inert organic solvent, for example, carbon disulfide, hydrocarbons such as benzene, toluene and the like, chlorinated hydrocarbons such as dichloromethane, carbontetrachloride, chloroform and the like, and ethers such as diethylether, tetrahydrofuran, dioxane and the like. The temperature of the reaction is not critical. Conveniently, it may be in the range of about 0C. and about the reflux temperature of the reaction mixture.

The various other process aspects of the invention are exemplified by the following reaction schemes Ila, IIb, Illa, IIIb and IV.

Scheme Ila XIIIa IXc formula XIa, its antipode or racemate to 7-acyl-lnitrose-decahydro2H-pyrido[3(R),4(S)-d]-azepin- 2-one of formula XIIa, its antipode or racemate, respectively, is carried out utilizing a nitrocating agent, such as, for example, sodium nitrite or dinitrogen tetroxide, Conveniently, the reaction can be conducted in the presense of a solvent, for example, an organic acid such as acetic acid, or a chlorinated hydrocarbon such as carbon tetrachloride. The nitrosation is conveniently conducted at a temperature within the range of about 0C. to about room temperature, preferably at 0C.

The compound of formula XIIa is converted to lacyl-3(R)-vinyl-4(S)-piperidineacetic acid of formula XIIIa, its antipode or racemate, respectively, by pyrolysis. Conveniently,the pyrolysis is conducted at a temperature within the range of about room temperature to about 200C preferably at a temperature within the range of about C. to about C. Conveniently, a high boiling solvent such as xylene, decaline and the like, can be utilized in the reaction.

The compound of formula XIIIa is converted to 1- acyl(or l-H)-3(R)-vinyl-4(S)-piperidineacetic acid ester of formula IXc, its antipode or racemate, respectively, utilizing an esterifying agent, for example, a lower alkanol, such as methanol, ethanol, propanol and the like, in the presence of, for example, an inorganic acid such as hydrochloric acid, sulfuric acid and the 19 like. When R is hydrogen, however, the esterification is preceded by hydrolysis in the presence of, for example, an aqueous inorganic acid, such as hydrochloric acid, sulfuric acid and the like.

Compounds of formula XIa, wherein R is alkyl, for instance, ethyl, can be prepared as described in Scheme lV.

Scheme IIb XIb XIII b wherein R R and R are as previously described. In a like manner, in Reaction Scheme [[11, the conversion of 7-acyl-decahydro-2H-pyrido[3(S),4(S)-d]aze- XIa pin-2-one of Formula Xlb, its antipode or racemate to 7-acyll -nitroso-decahydro-2H-pyrido 3 S ),4( S

d]azepin-2-one of Formula XIIb, its antipode or racemate, respectively, is carried out. The compound of Formula XlIb is converted to l-acyl-3(S)-vinyl-4(S)- piperidineacetic acid of Formula XIIIb, its antipode or racemate, respectively, by pyrolysis. The compound of XIIb Formula XIIIb is converted to l-acyl(or l-H )-3(S)- vinyl-4(S)-piperidineacetic acid ester of Formula IXd, its antipode or racemate, respectively.

Scheme Ill Nag XIV

wherein R R and R are as previously described.

In Reaction Scheme Illa, 7-acyl-decahydro-2H- pyrido[3(R),-4(S)-d]azepin-2-one of formula Xla, its antipode or racemate is converted to 1-acyl-3(R)-(2- aminoethyl)-4(S)-piperidineacetic acid ester of for-,

mula XIVa, its antipode or racemate, respectively, utilizing an alcoholizing agent, for example, a lower alkanol such as methanol, ethanol, propanol and the like, in the presence of, for example, anhydrous inorganic acid such as hydrochloric acid, sulfuric acid and the like. Conveniently, the alcoholysis is conducted at a temperature within the range of about room temperature to about the boiling point of the alkanol.

The compound of formula XlVa, is converted to l-acyl-3(R)-( Z-dimethylaminoethyl)-4(S)-piperidineacetic acid ester of formula XVa, its antipode or racemate, respectively, utilizing a methylatingagent such as, for example, formic acid/formaldehyde mixture or formaldehyde/Raney nickel. The N-methylation is conveniently conducted at a temperature within the range of about room temperature to about the boiling point of the methylating agent.

XIb

.- Continued ooP XVIa

The compound of formula XVa is converted to lacyl-3 (R 2-dimethylaminoethyl )-4(S )-piperidineacetic acid ester N-oxide of formula XVIa, its antipode or'r acemate, respectively, utilizing an oxidizing agent, for example, hydrogen peroxide or a perorganic acid such as, peracetic acid. The oxidation is conveniently conducted in the presence of a solvent, for example, lower alkanol', such as methanol, ethanol, propanol and the like, or a hydrocarbon such as benzene and the like. The oxidation is conveniently conducted at a temperature within the range of about 0 to about room temperature, preferably at 0C.

The compound of formula XVIa is converted to 1- acyl(or 1-H)3(R)-vinyl4(S)-piperidineacetic acid ester of formula lXc, its antipode or racemate, respectively, by pyrolysis. Such pyrolysis is conveniently conducted at a temperature in the range of about to about 200C, preferably at a temperature within the range of about toab out l25C. When R is hydrogen, however, the pyrolysis is followed by hydrolysis and reesterification.

Scheme IIlb "'Continued XVb XVIb piperidineace ticacid ester of Formula XVb, its antipode or racernate, respectively. Th; compound) of Formula XVb is conyerte'd to l -acyl-3(S) -(2-dime- 35 thylaminotliyl) 4(S)-piperidineacetic' acid ester N- oxide'of Formula XVlb, its antipode or racemate, respectively. The compound of Formula XVlb is converted to l-acyl (o'r l-H) 3()-v inyl-4(S)-piperidinea-4 cetic acid ester of Formula IXd, its antipode or racemate.

SchernelV whereinR R and R are as previously described. In a like manner, in Reaction Scheme lllb, 7-acyldecahydro-2H-pyrido[3(S),4(S)-d]azepin-2-one of Formula XIb, its an tipode or racemate is converted to l-acyl-3(S)-(2-aminoethyl)-4(S)-piperidineacetic acid ester of Formula XIVb; its antipode or racemate, re-4 spectively. The compound of Formula XI Vb is converted to l-acyl-3(S)-(2-dimethylaminoethyl)-4(S)- O/kfia XVII XIX A OAR! XIa 0 Re XVIIIa 25 26 Continued XVIIIb I Xlb wherein R is as previously described. compounds listed in the above paragraph are useful In the Reaction Scheme IV, racemic 2-acylint rmediates.

1-,3,4,7,8,8a-hexahydro-6(2H )-isoquinolone of formula In Still another aspect, the invention relates to com- XVII is converted to the racemic cis and trans 2-acylpounds of the formulas octahydro-6(2H)-isoquinolones of formula XVIIIa and XVIIIb, respectively, utilizing a hydrogenating agent,

for example, hydrogen in the presence of palladium or rhodium catalyst. Conveniently, the hydrogenation can be conducted in the presence of a solvent, for example,

a lower alkanol such as methanol, ethanol, propanol and the like, with or without an inorganic acid such as hydrohalic acid, for example, hydrochloric acid and the like. The hydrogenation can be conveniently con- R ducted at a temperature within the range of about room temperature and about 50C. 1 1

The racemates of the compounds of formula XVIIIa or XVIIIb are resolved to the corresponding optical antipodes by conventional methods which are further II illustrated by Examples 3, 4, 5.

The conversion of 2-acyl-4a(S),8a(R)-octahydro- 6(2H)-isoquinolone of formula XVIIIa, its antipode or and racemate to 7-acyldecahydro-2I-I-pyrido[3(R),4(S)- d]azepin-2-one of formula XIa, its antipode or racemate, respectively, is carried out utilizing the known Schmidt rearrangement, i.e., the reaction of the compound of formula XVIIIa with sodium azide in the presence of an inorganic acid such as sulfuric acid or polyphosphoric acid, with or without solvent, at a temperature within the range of from about 0 to about 150C. In a like manner, 2acyl-4a(S),8a(S)-octahydro- 6(2H)-isoquinolene of Formula XVIIIb, its antipode or 1 n racemate is converted to 7-acyl-decahydro-2I-lpyrido[3(S),4(S)d]azepin-2-one of Formula XIb, its antipode or racemate, respectively. 4

The racemic compound of Formula XVII is converted to the racemic 2-acyl-l,2,3,4,7,8,9,9a-octahydro-6I-I-pyrido[3,4-dlazepin-6-one of Formula XIX- utilizing the Schmidt rearrangement as hereinbefore wherein n is O to 2; R is vinyl or lower alkyl; R is described. The compound of Formula XIX is converted hydrogen, hydroxy, lower alkyl, lower alkoxy, trito the racemic compound of Formula XIa utilizing a fluoromethyl, halogen, or when n is 2, R taken hydrogenating agent such as hydrogen in the presence together with an adjacent R is also methylenediof a catalyst, such as rhodium or palladium, in a soloxy; when R is hydrogen, R is C -C alkoxy, vent, for example, as alkanol, such as ethanol, methalower lk l, trifl o th l or h l when R is nol and the like, in the presence of an inorganic acid, other th h d d n i 1, R, i l w r alkoxy, such as hydrochloric acid. lower alkyl, hydroxy, hydrogen, trifluoromethyl,

In another aspect, the invention relates to the comh l t k n t ther with an adjacent R is pounds of formulas lb, IIb, IIIb, IVb, Va, Vb, Vld, VIb, methylenedioxy; and when R is other than hydrovIIlZ, VIII), VIIIa, VIIIb, lXb, XIa, XIb, XIIa, XIII), gen and n is 2 R7 is hydrogen and their antipodes XIIIb, XIVa, XIVb, XVa, XVb, XVla, XVIb and XIX. d racemates,

The compounds of formulas Ib and IIb are useful as Al i l d d i th purview f h i ti are antimalarial and antiarrhythmic agents; all the other compounds of the formulas wherein n is to 2; R is vinyl or lower alkyl; R is hydrogen, hydroxy, lower alkyl, lower alkoxy, trifluoromethyl, halogen, or when rt is 2, R taken together with an adjacent R is also methylenedi- 5 oxy; when R is hydrogen, R is C -C alkoxy,

lower alkyl, trifluoromethyl or halogen; when R is CH other than hydrogen and n is 1, R is lower alkoxy, lower alkyl, hydrogen, trifluoromethyl, halogen, or

I 0 taken together with an adjacent R is methylenedioxy; and when R is other than hydrogen and n is 2, R is hydrogen and their antipodes and race- IIId mates.

As is evident from the above R, or R or the like are individually selected from the various groupings hereinbefore described. Moreover, when m or n is 2, R or and R or the like can additionally form with an adjacent R or R or the like the methylenedioxy radical. Thus, either when m or n is l or 2, R or R or the like can individually also represent hydrogen, hydroxy, halogen,

lower alkyl, lower alkoxy or trifiuoromethyl. Additionally, when m or n is 2, two adjacent groupings of R or R can together represent methylenedioxy.

In yet another aspect, the invention relates to compounds of the formulas wherein R is methyl or C C lower alkyl, their antipodes and racemates. Compounds of formulas IIIc, IIId, [Va and IVd are useful intermediates.

In still another aspect, the invention relates to compounds of the formulas IIIf.

and

(II-I 0 wherein R is methyl or C -C lower alkyl, their antipodes and racemates. Compounds of formulas llle, IIlf, IVe and lVf are useful intermediates.

In a further aspect, the invention relates to compounds of the formulas IIC wherein n is O to 2; R is vinyl or lower alkyl; R is hydrogen, hydroxy, lower alkyl, lower alkoxy, trifluoromethyl or halogen, and when n is 2, R taken together with an adjacent R is also methylenedioxy; when R is hydrogen, R is C -C alkoxy,- lower alkyl, trifluoromethyl or halogen; when R is other than hydrogen and n is 1, R is lower alkoxy, lower alkyl, hydrogen, trifluoromethyl or halogen, or taken together with an adjacent R is methylenedioxy; and when R is other than hydrogen and n is 2, R is hydrogen, and their antipodes and racemates, and pharmaceutically acceptable acid addition salts.

Exemplary of the compounds of formulas lo and [1c are: 6,8-dimethoxy-a(R)-[(S)-ethyl-4(S)-quinuclidin- 2(S)-yll-4-quinolinemethanol [hereinafter referred to as 6,8-dimethoxy-3-epi-dihydrocinchonidine] its antipode and racemic analog;

7-chloro-a(R)-[5(S)-ethyl-4(S)-quinuclidin-2(S-)- yll-4-quinolinemethanol [hereinafter referred to as 7-chloro-3-epi-dihydrocinchonidine] its antipode and racemic analog;

6,7-methylenedioxy-a(R)-[ 5 (S)-ethyl-4(S)-quinuclidin-2(S )-yl]-4-quinolinemethanol [hereinafter referred to as 6 ,7 -methylenedioxy-3-epi-dihydrocinchonidine] its antipode and racemic analog; 7-trifluoromethyl-a( R H 5 (S )-ethyl-4(S )-quinuclidin-2(S )-yl]-4-quinolinemethanol [hereinafter referred to as 7'-trifluoromethyl-3'epi-dihydrocinchonidine] its antipode and racemic analog;

6,8-dimethoxy-a(S)-[5(S)-ethyl-4(S)-quinuclidin- 2(R)-yl]-4-quinolinemethanol [hereinafter referred to as 6',8'-dimethoxy-3-epi-dihydrocinchonine] its antipode and racemic analog;

7-chloro-a(S)-[5(S)-ethyl-4(S)-quinuclidin-2(R)- yl]-4-quinolinemethanol [hereinafter referred to as 7'-chloro-3-epi-dihydrocinchonine] its antipode and racemic analog;

6,7-methylenedioxy-a(S)-[5(S)-ethyl-4(S)-quinuclidin-2(R)-yl]-4-quinolinemethanol [hereinafter referred to as 6',7'-methylenedioxy-3-epi-dihydrocinchonine] its antipode and racemic analog;

7-trifluoromethyl-a( S 5 S )-ethyl-4 S )-quinuclidin-2(R)-yl]-4-quinolinemethanol [hereinafter referred to as 7'-trifluoromethyl-3-epi dihydrocinchonine] its antipode and racemic analog.

Also included in the purview of the invention are compounds of the formulas CHQO and

IId

wherein R, is vinyl, methyl or C -C alkyl, their antipodes and racemates and pharmaceutically acceptable acid addition salts.

Also included in the purview of the invention are compounds of the formula:

The antipode of 6-methoxy-a(R)-[5(S)-ethyl-4(S)- quinuclidin-2(S)-yl]-4-quinolinemethanol [hereinafter referred to as 6-methox y-3-epi-dihydrocinchonidine or 3-epi-dihydroquinine] and its racemic analog (Compound A) and The antipode of 6-methoxy-a(S)-[5(S)-ethyl-4(S)- quinuclidin-2(R)-yl]4-quinolinemethanol [hereinafter referred to as 6methoxy-3epi-dihydrocinchonine or 3-epi-dihydroquinidine] and its racemic analog (Compound B).

The compounds of formulas Ic, Id, Ilc and lId, as well as Compounds A and B, are useful also as antimalarial and antiarrhythmic agents.

The compounds of the formula lXa have demonstrated cardiovascular activity, such as, hypotensive activity. The pharmacologically useful cardiovascular activity is demonstrated in warm-blooded animals utilizing standard procedures. For example, the test compound is administered to anesthetized (30 mg/kg sodium pentobarbital), artificially respired (Palmer Pump) dogs. Femoral arterial blood pressure and respiratory resistance (measured in terms of pressure) are recorded on a direct writing oscillographic recorder. A series of control responses of the blood pressure and respiration are obtained and duplicated. The control procedures used are: intravenously administered norepinephrine (l 'y/kg), histamine (l 'y/kg), serotonin (25 -y/kg) and hypertensin (0.5 -y/kg), as well as the bilaterial occlusion of the carotid arteries and the electrical stimulation of the central portion of a severed vagus nerve (SV, 50 c.p.s., 10 sec.). Each of the control procedures is. administered at 5-minute intervals. Five minutes after the series of control responses, the drug to be tested is intravenously administered and its effects recorded. The series of control procedures is repeated after dosing to determine the effect of the compound on these standard responses. If the control responses are unaltered by the test drug, a second compound is administered and the procedure repeated. If the test compound alters the blood pressure or the control responses, the control procedures are repeated at convenient intervals until the animal has returned to its predose status or a new physiological status is established.

When meroquinene-t-butylester d-monotartrate of the formula N Ill dmonotartrate is utilized as the test substance at a dose of 4 mg/kg. intravenously, their following results are obtained:

blood pressure 25 for 35 minutes serotonin N.E. Central Vagus Stimulation slight inhibition Carotid Occlusion blocking Hypertension N.E. Norepinephrine slight inhibition Histamine slight inhibition The compounds of Formula lXa also exhibit antiestrogenic activity. This useful estrogenic activity is demonstrated in warm-blooded animals. For example, the test compound is administered once daily for three consecutive days to groups of ten immature fe male rats (40-5O grams). On the first treatment day, all

rats are injected subcutaneously with 0.25 meg. estradiol in sesame oil. On the fourth day, uteri are removed at autopsy and weighed on a torsion balance.

When meroquinene-t-butylester d-monotartrate is utilized as the test substance at a dosage of l mg/kg. p.o., an 1 1 percent antiestrogen inhibition is observed with a l2 percent uterine change.

The compounds of formulas la, Ila, lb and lIb, including compounds of the formulas 10, Id, lie and H11, as well as compounds A and B, and their pharmaceutically acceptable acid addition salts possess antimalarial and antiarrhythmic properties and are therefore useful as antimalarial and antiarrhythmic agents. Their pharmacologically useful antiarrhythmic activity is demonstrated in warm-blooded animals utilizing standard procedures, for example, the test compound is administered to prepared mongrel dogs. The chest cavity of the experimental animal previously anesthetized using a combination of sodium barbitol, 300 mg/kg. and pentobarbitol, 15 mg/kg., i.e., is opened up through the third right interspace under artificial respiration and the pericardium is cut and sutured to the wall of the thorax so as to maintain the heart in a pericardial cradle throughout the course of the test procedure. Arterial pressure is monitored by inserting a polyethylene cannula into the aorta via the left carotid artery and is measured with an appropriate Statham pressure transducer. During the course of the experiment, electrical activity of the heart is viewed both on an oscilloscope and recorded on a Sanborn polyviso using standard ECG lead ll. The heart is also observed visually. The antiarrhythmic assay of the test drug is undertaken using a modification of the method of Scherf and 0 Chick, 1951. A dripping of 1 percent solution of acetyl- When 6'-methoxy-a(R)-[5(R)-ethyl-4(S)-quinucli- 65 din-2(S)-yl]-4-quinoline methanol is utilized as the test substance at a dosage of about 4.0 mg/kg., an antifibrillatory effect is observed for more than minutes.

Their pharmacological useful antimalarial activity is demonstrated in warm-blooded animals using standard procedures, for example, the test substance is administered to albino mice in variable amounts. Albino mice are inoculated with about -10 million red cells infected with P. Bergei. Treatment is started on the first day after inoculation, and the drug is administered per os during 4 consecutive days. On the seventh day of infection, smears are made, stained with giemsa and microscopically examined for P. Bergei.

When racemic 7'-methoxy-dihydrocinchonidine dihydrochloride or racemic 7-methoxy-dihydrocinehonine dihydrochloride is utilized as the test substance at dosages in the range of 125 mg/kg. to about 250 mg/kg., the microscopical examination of the blood smears is free of P. Bergbei (negative). When 6'- methoxy-a(R)-[5(R)-ethyl-4(S)-quinuelidin-2(S)-yl]- 4-quinolinemethanol[dihydroquinine] or 6-methoxya(R)-[5(R)-ethyl-4(S)-quinuclidin-2(S)-yl]-4- quinolinemethanol is utilized as the test substance at a dose of about 200 mg/kg., the microscopical examination of the blood smears is free of P. Berghei (negative). The compounds of formulas Ia, Ila, Ib and Ilb, including the compounds of formulas lc, Id, He and 11d, as well as compounds A and B, and their pharmaceutically acceptable acid addition salts have effects qualitatively similar, for example, to those of quinine and quinidine, known for their therapeutic uses and properties. Thus, the compounds of the invention demonstrate a pattern of activity associated with antimalarials and antiarrhythmics of known efficacy and safety.

Furthermore, the compounds of the formulas Ia, Ila, lb and Ilb, including the compounds of formulas Ic, Id, 1k and IId, as well as compounds A and B, can be utilized as flavoring agents in beverages in the same manner as quinine is now used for this purpose.

The compounds of formulas Ia, lIa, lb and [1b, including the compounds of formulas 10, Id, lie and Ild, as well as compounds A and B, form acid addition salts and such salts are also within the scope of this invention. Thus, the compounds of formulas Ia, Ila, lb and IIb, including the compounds of formulas Ic, Id, Ilc and Ild, as well as compounds A and B, form pharmaceutically acceptable addition salts with, for example, both pharmaceutically acceptable addition salts with, for example, both pharmaceutically acceptable organic and inorganic acids, such as acetic acid, succinic acid, formic acid, methanesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, and the like.

The products of the invention can be incorporated into standard pharmaceutical dosage forms, for example, they are useful for oral or parenteral application with the usual pharmaceutical adjuvant materials, e.g., organic or inorganic inert carrier materials such as water, gelatin, lactose, starch, magnesium stearate, talc, vegetable oils, gums, polyalkyleneglycols, and the like. The pharmaceutical preparations can be employed in a solid form, e.g., as tablets, troches, suppositories, capsules, or in liquid form, e.g., as solutions, suspensions or emulsions. The pharmaceutical adjuvant material can include preservatives, stabilizers, wetting or emulsifying agents, salts to change the osmotic pressure or to act as buffers. They can also contain other therapeutically active materials.

The quantity of active medicament which is present in any of the above-described dosage forms is variable.

The frequency with which any such dosage form will be administered will vary, depending upon the quantity of active medicament present therein, and the needs and requirements of the pharmacological situation.

Due to the possible different spatial arrangements of their atoms, it is to be understood that the compounds of this invention may be obtained in more than one possible stereoisomeric form. The novel compounds, as described and claimed, are intended to embrace all such isomeric forms. Accordingly, the examples included herein are to be understood as illustrative of particular mixtures of isomers or single isomers and not as limitations upon the scope of the invention. All temperatures are in degrees centigrade, unless otherwise mentioned.

EXAMPLE 1 Preparation of racemic cis 2-benzoyl-octahydro-6( 2N )-isoquinolone from racemic 2-benzoyl-l,3,4,7,8,8a-hexahydro-6(2N)-isoquinolone To a solution containin 151 g. of racemic 2 benzoyll,3,4,7,8,8a-hexahydro-6(2H)-isoquinolone in 3000 ml. of absolute ethanol were added 300 ml. of 3N aqueous hydrochloric acid and 30 g. of 5% rhodium on alumina catalyst. The mixture was hydrogenated at room temperature and atmospheric pressure until the uptake of hydrogen ceased. The catalyst was removed by filtration and washed thoroughly with ethanol. The filtrate was partially evaporated in vacuo, diluted with 3500 ml. of dichloromethane and washed with 3N aqueous hydrochloric acid, saturated aqueous sodium bicarbonate and sodium chloride solutions. The organic phase was dried over anhydrous sodium sulfate and evaporated to dryness to yield a crystalline product. Gas chromatographic analysis indicated that it contained 61.9% of racemic cis 2-benzoyl-octahydro- 6(2I-I )-isoquinolone and 13% of racemic trans 2-benzoyl-octahydro-6(2I-I)-isoquinolone. The product was recrystallized twice from benzene to give racemic cis 2-benzoyloctahydro-6(2I-I)-isoquinolone having a melting point of l47-l48.5.

EXAMPLE 2 Preparation of racemic trans 2-benzoyl-octahydro-6(2I-l)-isoquinolone from racemic 2-benzoyl-l ,3 ,4,7,8,8a-hexahydro-6(2I-I )-isoquinolone To a solution containing 25.5 g. of racemic 2-benzoyl-l ,3,4,7,8,8a-hexahydro-6(2l-I)-isoquinolone in 1000 ml. of ethanol were added 2.5 g. of 10% palladium on carbon catalyst and the mixture was hydrogenated at room temperature and 3 atmospheres pressure until the uptake of hydrogen ceased. The catalyst was removed by filtration and washed with 95% ethanol and dichloromethane. The filtrate was evaporated to dryness to yield an oil which crystallized on trituration with ether. The product was recrystallized twice from absolute ethanol to yield racemic trans 2-benzoyl-octahydro-6(2l-I)-isoquinolone, which after two additional recrystallizations from absolute ethanol, had a melting point of l57.5l59.

EXAMPLE 3 Preparation of 2-benzoyl-4(R),5(R)-dimethyl-l ,2,3',4',4'a(S),

7 ',8 ,8a(S)-octahydrospiro[1,3-dioxolane-2,6'(5 H isoquinoline] and 2'-benzoyl-4(R),5(R)-dimethyl-l ',2,3,4,4'a(R),7,- 8 ',8a(R)-octahydrospiro[ l ,3-dioxolane-2,6'(5 'H isoquinoline] To a solution containing 23.4 g. of rac. trans-2-benzoyloctahydro-6(lH)-isoquinolone in 2 1. of anhydrous benzene was added 2.24 g. of p-toluenesulfonic acid and 9.83 g. of ()-butane-2(R),3(R)-diol. The resulting solution was refluxed for 3 hours and the water which formed was collected in a water separator. After the addition of 18 ml. of pyridine, the mixture was diluted to 4 l. with benzene, washed four times with 100 ml. of water, dried over anhydrous sodium sulfate and evaporated to dryness in vacuo. The last traces of pyridine were removed by codistillation with toluene in vacuo. The crystalline residue, 29.62 g., was fractionally crystallized by repeating several times the following system:

29.62 g. mixture of ketals 6 hours reflux with distilled petroleum ether (b.p. 3060C) soluble part recrystallization from ethanol-water insoluble part recrystallization 9 from ether EXAMPLE 4 Preparation of 4a(S ,8a(S )-2-benzoyloctahydro-6( 2H )-isoquinolone EXAMPLE 5 Preparation of 4a( R),8a(R )-2-benzoyloctahydro-6( 2H )-isoquinolone A solution containing 0.329 g. of 2'-benzoyl 4(R),5(R)-dimethyl-1',2,3',4',4'a(R),7',8',8a(R)- octahydrospiro[ l ,3-dioxolane-2,6( 5 'H )-isoquinoline] in 50 ml. of acetic acid was heated at -105 for 4 hours and 40 minutes. The reaction mixture was evaporated in vacuo diluted with 500 ml. of benzene, washed with 50 ml. of 2N aqueous sodium carbonate and 3 times with 50 ml. of water, dried over anhydrous sodium sulfate and evaporated in vacuo to yield 0.256 g. of 4a(R),8a(R)-2-benzoyloctahydro-6(2H)- isoquinolone having a melting point of 151l53 (from absolute ethanol); [01] 62.60 (c 1.005, CHCl EXAMPLE 6 Preparation of racemic cis 7-benzoyl-decahydro-2H-pyrido[3,4-d]-azepin-2-one from racemic cis 2-benzoyl-octahydro-6( 2H )-isoquinolone To a suspension containing 20.6 g. of finely ground racemic cis 2-benzoyl-octahydro-6(2H)-isoquinolone in 800 g. of polyphosphoric acid were added 10.0 g. of sodium azide, and the mixture was stirred 16 hours at 55-60". After cooling at room temperature, the reaction mixture was poured onto crushedice. The resulting solution was made alkaline with solid sodium carbonate at 0, and was extracted thoroughly with dichloromethane. The organic phase was washed with water, dried over anhydrous sodium sulfate and evaporated to dryness in vacuo. The oily residue crystallized on trituration with acetone. Fractional crystallization of the crystalline product from the acetone yielded cis 7- benzoyl-decahydro-2l-lpyrido[3,4-d]azepin-2-one, which after one recrystallization from absolute ethanol and three recrystallizations from acetone had a melting point of 167l68.5.

EXAMPLE 7 Preparation of racemic trans 7benzoyl-decahydro-ZH-pyrid0[ 3 ,4-d1-azepin-2-one from racemic trans 2-benzoyl-octahydro-6(2H )-isoquinolone To a mixture containing 5.15 g. of trans 2-benzoyloctahydro-6(2H)-isoquinolone and 200 g. of polyphosphoric acid were added 2.5 g. of sodium azide and'the reaction mixture was stirred at 5560 for 16 hours. After cooling to room temperature, the polyphosphoric acid was hydrolyzed by addition of ice. The resulting solution was made alkaline with concentrated sodium carbonate solution and extracted thoroughly with di chloromethane. The extract was washed with water, dried over anhydrous sodium sulfate and evaporated to dryness to yield 5.45 g. of crystalline racemic trans 7-benzoyl-decahydro-2l-l-pyrido[3,4-d]-azepin-2-one. After recrystallization from ethanol/ether it had a melting point of 187189.

EXAMPLE 8 Preparation of 5a( S ),9a(S )-7-benzoyldecahydro-2H-pyrido[ 3 ,4- d]azepin-2-one To a mixture of finely ground 2.57 g. of 4a(S),8a(S)- 2-benzoyloctahydro-6(2H)-isoquinolone and 100 g. of polyphosphoric acid wasadded 1.3 g. of sodium azide. The reaction mixture was stirred at 5560C. (bath) for 16 hours, cooled to room temperature and poured into ca. 380 g. of crushed ice. After the ice had melted, the resulting solution was made alkaline with 6N aqueous sodium carbonate (370 ml) and extracted 3 times with 300 ml. of methylene chloride. Methylene chloride extract was washed 3 times with 40 ml. of water dried over anhydrous sodium sulfate and evaporated to dryness, to give 2.72 g. of crystalline 5a(S),9a(S)-7- benzoyldecahydro-2H-pyrido[3,4-d]azepin2-one. From absolute ethanol it crystallized with one mole of ethanol, m.p. 200203C., [12:1 37.83 (0 1.0547, CHCI on drying loses ethanol to give anhydrous form, m.p. 90100.

EXAMPLE 9 Preparation of racemic 2-benzoyl-l ,2,3 ,4,7,8,9,9a-octahydro-6H-pyrido[3 ,4- d]azepin-6-one from racemic 2-benzoyl-1 ,3 ,4,7,8,8a-hexahydro-6(21-1)-isoquinolone To a suspension containing 1.02 g. of finely ground racemic 2-benzoyl-1,3 ,4,7,8,8a-hexahydro-6(2H)- isoquinolone in 40 g. of polyphosphoric acid was added 0.5 g. of sodium azide and the reaction mixture was stirred at 120 for 30 minutes. After cooling to room temperature, ice was added. The resulting solution was made alkaline with saturated aqueous sodium carbonate at 0 and was extracted with dichloromethane. The dichloromethane extract was washed with water, dried over anhydrous sodium sulfate and evaporated to dryness. The product was crystallized by trituration with acetone. to give racemic 2-benzoyl-1,2,3,4,7,8,9,9aoctahydro-6H-pyrido[3,4-d]azepin-6-one having a melting point of 2l922l.

EXAMPLE 10 Preparation of racemic cis 7-benzoyl-decahydro-2l-l-pyrido[3,4-d]-azepin-2-one from racemic 2-benzoyl-l ,2,3 ,4,7,8,9,9a-octahydro-6H-pyrido[3,4- d]azepin-6-one To a solution containing 5.4 g. of racemic 2-benzoyl- 1,2,3 ,4,7 ,8,9,9a-octahydro-6l-l-pyrido[3,4-d]azepin- 6-one in 450 ml. of absolute ethanol were added 10 ml. of 3N aqueous hydrochloric acid and 5.4 g. of rhodium on alumina catalyst. The reaction mixture was hydrogenated at room temperature and atmospheric pressure until the uptake of hydrogen ceased. Thereafter, the catalyst was removed by filtration and washed thoroughly with ethanol. The filtrate was neutralized with 2N aqueous sodium carbonate and evaporated to a small volume in vacuo. The residue was extracted with 1000 ml. of dichloromethane. The extract was washed with water, dried with anhydrous sodium sulfate and evaporated to dryness. The non-crystalline product exhibited an lR-spectrum identical to that of the racemic cis 7-benzoyl-decahydro-ZH-pyrido[3,4- d ]azepin-Z-one of Example 6, and after being recrystallized twice from acetone, had a melting point of 162-165.

r EXAMPLE .11

Preparation of racemic cis 1-benzoyl-3-(2-aminoethyl)-4-piperidineaceticacid ethyl ester from racemic cis 7-benzoyl-decahydro-2H-pyrido 3 ,4-d azepin-2-one A solution containing 2.8 g. of racemic cis 7-benzoyldecahydro-2H-pyrido[3,4-d]azepin-2-one in 500 ml. of 5% ethanolic hydrochloric acid was refluxed for hours. Thereafter, the solvent was removed by evaporation in vacuo. The residue was taken up in 1200 ml. of dichloromethane. The resulting solution was shaken with a solution containing 0.53 g. of sodium carbonate in 10 ml. of water, dried over anhydrous sodium sulfate and evaporated to yield oily racemic cis 1-benzoyl-3- (2-aminoethyl)4-piperidineacetic acid ethyl ester.

EXAMPLEv 12 Preparation of racemic trans l-benzoyl-3-( 2-aminoethyl)-4-piperidinecetic acid ethyl ester from racemic trans 7-benzoyl-decahydro-2l-l-pyrido[3,4-d]azepin-2-one EXAMPLE 13 Preparation of racemic cis 1-benzoyl-3-vinyl-4-piperidineacetic acid ethyl ester (racemic N-benzoylmeroquinone ethyl ester) from racemic cis Y 1-benzoy1-3-(2-aminoethyl)-4-piperidineacetic acid ethyl ester A mixture containing 1.91 g. of racemic cis l-benzoy13-(2-aminoethy1)-4-piperidineacetic acid ethyl ester, 1.38 g. of formic acid and 1.05 g. of 37% formaldehyde was heated for 1 hour at 100. After cooling to room temperature, 3.5 ml. of concentrated hydrochloric acid were added and the mixture thus obtained was evaporated to dryness in vacuo. The residue was dissolved in 50 ml. of water. The solution was washed by shaking with ether, made alkaline to about a pH 8 with 2N sodium carbonate and extracted thoroughly with dichloromethane. The extract was washed with water, dried over anhydrous sodium sulfate and evaporated to dryness in vacuo to give oily racemic cis l-benzoyl3-(2- dimethylaminoethyl)-4-piperidineacetic acid ethyl ester. To the stirred solution containing this product in 10 ml. of methanol were added 2 ml. of 30% aqueous hydrogen peroxide at 0. The reaction mixture was warmed to room temperature and stirred for 16 hours. The excess of hydrogen peroxide was decomposed by addition of platinum black with stirring for 1 hour at 0. The platinum black was separated by filtration and washed with methanol. The filtrate was evaporated to dryness in vacuo to yield racemic cis l-benzoyl-3-(2 

1. A COMPOUND OF THE FORMULA
 2. A compound in accordance with claim 1, i.e., 7-chloro-4-( Alpha -(5(R)-vinyl-4(S)-quinuclidin-2(S)-yl)-methyl)-quinoline.
 3. A compound in accordance with claim 1, i.e., 6,8-dichloro-4-( Alpha -(5(R)-vinyl-4(S)-quinuclidin-2(S)-yl)methyl)-quinoline, its antipode and racemate.
 4. A compound of the formula
 5. A compound in accordance with claim 4, i.e., 7-chloro-4-( Alpha -(5(R)-vinyl-4(S)-quinuclidin-2(R)-yl)-methyl)-quinoline.
 6. A compound in accordance with claim 4, i.e., 6,8-dichloro-4-( Alpha -(5(R)-vinyl-4(S)-quinuclidin-2(R)-yl)-methyl)-quinoline, its antipode and racemate.
 7. A compound of the formula
 8. A compound in accordance with claim 7, racemic 6,8-dimethoxy-Alpha (R)-(5(S)-ethyl-4(S)-quinuclidin-2(S)-yl)-4-quinolinemethanol.
 9. A compound in accordance with claim 7, racemic 7-chloro-Alpha (R)-(5(S)-ethyl-4(S)-quinuclidin-2(S)-yl)-4-quinolinemethanol.
 10. A compound in accordance with claim 7, racemic 6,7-methylenedioxy- Alpha (R)-(5(S)-ethyl-4(S)-quinuclidin-2(S)-yl)-4-quinolinemethanol.
 11. A compound in accordance with claim 7, racemic 7-trifluoromethyl- Alpha (R)-(5(S)-ethyl-4(S)-quinuclidin-2(S)-yl)-4-quinolinemethanol.
 12. A compound of the formula
 13. A compound in accordance with claim 12, racemic 6,8-dimethoxy- Alpha (S)-(5(S)-ethyl-4(S)-quinuclidin-2(R)-yl)-4-quinolinemethanol.
 14. A compound in accordance with claim 12, racemic 7-chloro-Alpha (S)-(5(S)-ethyl-4(S)-quinuclidin-2(R)-yl)-4-quinolinemethanol.
 15. A compound in accordance with claim 12, racemic 6,7-methylenedioxy- Alpha (S)-(5(S)-ethyl-4(S)-quinuclidin-2(R)-yl)-4-quinolinemethanol.
 16. A compound in accordance with claim 12, racemic 7-trifluoromethyl- Alpha (S)-(5(S)-ethyl-4(S)-quinuclidin-2(R)-yl)-4-quinolinemethanol.
 17. Racemic 6-methoxy- Alpha (R)-(5(S)-ethyl-4(S)-quinuclidin-2(S)-yl)-4-quinolinemethanol.
 18. Racemic 6-methoxy- Alpha (S)-(5(S)-ethyl-4(S)-quinuclidin-2(R)-yl)-4-quinolinemethanol.
 19. A compound of the formula
 20. A compound of the formula 